Coherus BioSciences Inc
Coherus BioSciences (CHRS) is a US-based biotechnology firm specialising in biosimilar medicines—biologic therapies developed to be highly similar to already authorised biologics. The company has pursued commercialisation of oncology-support treatments and other biosimilars while maintaining an early-stage pipeline. With a market capitalisation of about $202.24 million, Coherus faces the typical dynamics of small-cap biotechs: growth opportunity from successful product launches and partnerships, balanced against clinical, regulatory and pricing pressures. Investors should note risks including regulatory approvals, competition from other biosimilars and originator biologics, and potential cash‑flow constraints that can lead to dilution. This summary is for general educational purposes only and is not personal investment advice; consider your objectives, risk tolerance and seek independent guidance before investing. Past performance is not indicative of future results and the value of equities can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Coherus BioSciences stock, expecting its price to rise significantly.
Financial Health
Coherus BioSciences is doing well with solid revenue and cash flow, indicating financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CHRS
China's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Biosimilars focus
Coherus targets established biologic markets with lower‑cost alternatives; successful uptake can drive sales, though adoption varies by payer and region.
Commercial traction
Existing launches and partnerships can support revenue growth, but competition and pricing pressure may limit margins and market share.
Regulatory & funding
Approval pathways and reimbursement rules shape prospects; small‑cap balance sheet constraints may require financing, which can dilute holders.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
